Proteon Therapeutics Company Profile (NASDAQ:PRTO)

About Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics logoProteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $41.4 million
  • Outstanding Shares: 17,619,000
Average Prices:
  • 50 Day Moving Avg: $1.79
  • 200 Day Moving Avg: $1.49
  • 52 Week Range: $1.10 - $11.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.53
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.67 per share
  • Price / Book: 1.41
  • EBITDA: ($26,350,000.00)
  • Return on Equity: -72.02%
  • Return on Assets: -64.41%
  • Current Ratio: 8.00%
  • Quick Ratio: 8.00%
  • Average Volume: 75,355 shs.
  • Beta: 1.7
  • Short Ratio: 2.01

Frequently Asked Questions for Proteon Therapeutics (NASDAQ:PRTO)

What is Proteon Therapeutics' stock symbol?

Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."

How were Proteon Therapeutics' earnings last quarter?

Proteon Therapeutics, Inc. (NASDAQ:PRTO) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.11. View Proteon Therapeutics' Earnings History.

When will Proteon Therapeutics make its next earnings announcement?

Proteon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Proteon Therapeutics.

Where is Proteon Therapeutics' stock going? Where will Proteon Therapeutics' stock price be in 2017?

8 brokerages have issued twelve-month price objectives for Proteon Therapeutics' stock. Their predictions range from $2.00 to $21.00. On average, they anticipate Proteon Therapeutics' stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Proteon Therapeutics.

What are analysts saying about Proteon Therapeutics stock?

Here are some recent quotes from research analysts about Proteon Therapeutics stock:

  • 1. According to Zacks Investment Research, "Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. " (7/13/2017)
  • 2. Robert W. Baird analysts commented, "Focus of the call was on changes to the ongoing PATENCY-2 study of vonapanitase, following disappointing results from the first identically designed PATENCY-1 study announced late last year. Key changes, supported by the FDA, include a reordering of the primary endpoint (now a co-primary) and expanding the study (300 to 500 patients), with data now expected in 4Q18 (2Q18 previously). While we are encouraged by a potential path forward for vonapanitase, lack of meaningful updates near-term keeps us on the sidelines." (3/16/2017)
  • 3. Maxim Group analysts commented, "Proteon reported YE16 with a net loss of $28.5M and ended the year with $41M in cash on the balance sheet." (3/16/2017)

Who are some of Proteon Therapeutics' key competitors?

Who are Proteon Therapeutics' key executives?

Proteon Therapeutics' management team includes the folowing people:

  • Paul J. Hastings, Chairman of the Board
  • Timothy P. Noyes, President, CEO, Director
  • George A. Eldridge, Chief Financial Officer, Senior Vice President, Treasurer, Assistant Secretary, IR Contact Officer
  • E. Scott Toner, Senior Vice President - Marketing
  • Steven K. Burke M.D., Senior Vice President, Chief Medical Officer
  • Matthew Paul Kowalsky, Vice President, Legal and Secretary
  • Daniel P. Gottlieb, Vice President - Corporate Development
  • Jonathan Leff, Director
  • Hubert Birner Ph.D., Independent Director
  • Garen G. Bohlin, Independent Director

Who owns Proteon Therapeutics stock?

Proteon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FLYNN JAMES E (9.99%), FLYNN JAMES E (9.99%) and TVM LIFE SCIENCE VENTURES VI LP (11.60%). Company insiders that own Proteon Therapeutics stock include George Arthur Eldridge and Timothy P Noyes. View Institutional Ownership Trends for Proteon Therapeutics.

How do I buy Proteon Therapeutics stock?

Shares of Proteon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Proteon Therapeutics' stock price today?

One share of Proteon Therapeutics stock can currently be purchased for approximately $2.35.

MarketBeat Community Rating for Proteon Therapeutics (NASDAQ PRTO)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Proteon Therapeutics (NASDAQ:PRTO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.13)
Consensus Price Target: $9.00 (282.98% upside)
Consensus Price Target History for Proteon Therapeutics (NASDAQ:PRTO)
Price Target History for Proteon Therapeutics (NASDAQ:PRTO)
Analysts' Ratings History for Proteon Therapeutics (NASDAQ:PRTO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformLowView Rating Details
8/9/2017HC WainwrightSet Price TargetHold$2.00LowView Rating Details
8/8/2017Cowen and CompanyReiterated RatingHoldLowView Rating Details
5/4/2017Maxim GroupSet Price TargetBuy$6.00HighView Rating Details
3/16/2017Robert W. BairdReiterated RatingNeutral$3.00LowView Rating Details
12/14/2016Raymond James Financial, Inc.Reiterated RatingStrong-Buy -> Market PerformN/AView Rating Details
12/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
12/14/2016Stifel NicolausDowngradeBuy -> Hold$19.00 -> $3.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Proteon Therapeutics (NASDAQ:PRTO)
Earnings by Quarter for Proteon Therapeutics (NASDAQ:PRTO)
Earnings History by Quarter for Proteon Therapeutics (NASDAQ PRTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.39)N/AView Earnings Details
8/7/2017Q2 2017($0.44)($0.33)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.43)($0.39)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.46)($0.43)ViewN/AView Earnings Details
5/9/2016Q1($0.41)($0.40)ViewN/AView Earnings Details
3/14/2016($0.34)($0.39)ViewN/AView Earnings Details
11/12/2015Q315($0.33)($0.33)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.31)ViewN/AView Earnings Details
5/13/2015($0.24)($0.28)ViewN/AView Earnings Details
3/20/2015($0.26)($0.24)ViewN/AView Earnings Details
11/25/2014($0.31)($31.03)$2.95 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Proteon Therapeutics (NASDAQ:PRTO)
2017 EPS Consensus Estimate: ($1.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.44)($0.44)($0.44)
Q2 20171($0.44)($0.44)($0.44)
Q3 20171($0.34)($0.34)($0.34)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)


Dividend History for Proteon Therapeutics (NASDAQ:PRTO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Proteon Therapeutics (NASDAQ:PRTO)
Insider Ownership Percentage: 36.30%
Institutional Ownership Percentage: 47.16%
Insider Trades by Quarter for Proteon Therapeutics (NASDAQ:PRTO)
Institutional Ownership by Quarter for Proteon Therapeutics (NASDAQ:PRTO)
Insider Trades by Quarter for Proteon Therapeutics (NASDAQ:PRTO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016George Arthur EldridgeCFOBuy4,000$5.78$23,120.00View SEC Filing  
12/1/2015Timothy P. NoyesCEOSell5,000$14.97$74,850.00View SEC Filing  
11/2/2015Timothy P. NoyesCEOSell5,000$13.50$67,500.00View SEC Filing  
10/1/2015Timothy P. NoyesCEOSell5,000$13.33$66,650.00View SEC Filing  
9/8/2015Timothy P. NoyesCEOSell5,000$13.55$67,750.00View SEC Filing  
7/7/2015Daniel Philip GottliebVPSell1,965$16.86$33,129.90View SEC Filing  
10/27/2014James E FlynnInsiderBuy691,713$10.00$6,917,130.00View SEC Filing  
10/27/2014Skyline Venture Partners QualiMajor ShareholderSell56,038$10.00$560,380.00View SEC Filing  
10/27/2014Timothy HainesDirectorBuy950,000$10.00$9,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Proteon Therapeutics (NASDAQ:PRTO)
Latest Headlines for Proteon Therapeutics (NASDAQ:PRTO)
DateHeadline logoProteon Therapeutics, Inc. (PRTO) Given Consensus Rating of "Hold" by Brokerages - September 30 at 8:34 PM logoHead-To-Head Contrast: NeuroDerm (NDRM) & Proteon Therapeutics (PRTO) - September 22 at 6:06 AM logoProteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017 - September 6 at 7:28 AM logoProteon Therapeutics, Inc. (PRTO) Receives Consensus Rating of "Hold" from Brokerages - September 5 at 9:00 PM logo-$0.39 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter - August 22 at 4:14 PM logoProteon Therapeutics, Inc. (PRTO) Forecasted to Earn Q3 2017 Earnings of ($0.34) Per Share - August 18 at 6:26 AM logoProteon Therapeutics' (PRTO) "Market Perform" Rating Reiterated at Oppenheimer Holdings, Inc. - August 16 at 2:41 PM logoProteon Therapeutics, Inc. (PRTO) Receives Average Recommendation of "Hold" from Brokerages - August 11 at 9:06 PM logoProteon Therapeutics' (NASDAQ:PRTO) "Hold" Rating Reiterated at Cowen and Company - August 9 at 12:38 AM logoProteon Therapeutics, Inc. (NASDAQ:PRTO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - August 8 at 11:14 AM logoProteon Therapeutics Announces Second Quarter 2017 Financial Results - August 8 at 6:22 AM logoProteon Therapeutics, Inc. (NASDAQ:PRTO) Expected to Post Earnings of -$0.45 Per Share - August 4 at 12:28 PM logoProteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing - August 3 at 7:06 AM logoProteon Therapeutics, Inc. (NASDAQ:PRTO) Receives Consensus Recommendation of "Hold" from Analysts - July 17 at 8:28 PM logoProteon Therapeutics, Inc. (PRTO) Expected to Post Earnings of -$0.45 Per Share - July 13 at 8:29 AM logoProteon Therapeutics Announces First Quarter 2017 Financial Results - May 10 at 7:33 PM logoPre-Open Stock Movers 05/10: (PRTO) (NVDA) (INCR) Higher; (YELP) (VSI) (FOSL) Lower (more...) - May 10 at 11:29 AM logoProteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase - May 10 at 11:29 AM logoProteon Therapeutics reports 1Q loss - May 10 at 8:13 AM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible ... - Business Wire (press release) - March 24 at 8:16 AM logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - March 22 at 7:30 AM logoProteon Therapeutics' (PRTO) Management Discuses Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial ... - Seeking Alpha - March 17 at 7:28 PM logoProteon CEO: New trial could be a path to market - March 17 at 7:28 PM logoPROTEON THERAPEUTICS INC Files SEC form 10-K, Annual Report - March 16 at 8:07 PM logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, - March 16 at 8:07 PM logoForm 8-K PROTEON THERAPEUTICS For: Mar 16 - - March 16 at 8:26 AM logoProteon Therapeutics (PRTO) Announces Two Presentations at ASDIN Meeting - February 6 at 7:26 PM logoProteon Therapeutics Inc. (PRTN) Has Plunged To A New Low After Study Failed - December 14 at 8:09 PM logoFailure in late clinical trial pummels Proteon Therapeutics stock - December 14 at 8:09 PM logo7:00 am Proteon Therapeutics announces that its first Phase 3 clinical trial with investigational vonapanitase did not meet its primary endpoint of improved primary unassisted patency compared to placebo (shares halted) - December 13 at 7:43 PM logoWaltham biotech's shares tank after kidney disease drug flunks trial - December 13 at 7:43 PM logoProteon Therapeutics downgraded by Robert W. Baird - December 13 at 7:43 PM logoProteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD - December 13 at 8:41 AM logoProteon Therapeutics' stock plummets after failed trial of kidney disease treatment - December 13 at 8:41 AM logoProteon Therapeutics Announces Second Quarter 2016 Financial Results - August 8 at 7:11 PM logo7 Stocks Under $10 to Trade for Big Post-Brexit Gains - August 3 at 10:11 AM logoHave You Ever Heard Of Proteon Therapeutics? - July 19 at 7:05 PM logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - June 13 at 8:01 AM logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and - May 9 at 8:02 AM logoProteon Therapeutics Reports Publication of Promising Nonclinical Results from Vonapanitase in Peripheral Artery Disease - April 13 at 9:33 AM logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement - January 22 at 8:31 AM logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi - October 19 at 8:02 AM



Proteon Therapeutics (PRTO) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.